Related Experiment Videos
[Inflammation and diabetes].
1Institut für Diabetesforschung und Med. Klinik 3, Lehrkrankenhaus München-Schwabing.
MMW Fortschritte Der Medizin
|November 16, 2004
Summary
Subclinical inflammation, even with mild glucose intolerance, drives diabetic complications and arteriosclerosis. Key inflammatory markers like NF-kappaB and TNF-alpha are implicated, suggesting anti-inflammatory treatments are crucial.
Area of Science:
- Endocrinology
- Cardiovascular Research
- Metabolic Syndrome
Background:
- Current diabetes research investigates the link between subclinical inflammation, diabetes, and arteriosclerosis.
- Chronic inflammation is associated with metabolic syndrome components and diabetic complications.
- Inflammation contributes to the development and progression of arteriosclerosis.
Purpose of the Study:
- To clarify the pathogenetic relationships between subclinical inflammation, diabetes, and arteriosclerosis.
- To identify key mediators and markers of the inflammatory cascade in this context.
Main Methods:
- Review of current diabetes research focusing on pathogenetic mechanisms.
- Identification of key inflammatory mediators and markers.
- Evaluation of therapeutic approaches targeting subclinical inflammation.
Main Results:
- Minimal disturbances in glucose tolerance trigger chronic, generalized inflammation.
- This inflammatory reaction links metabolic syndrome components.
- The inflammation cascade involves mediators such as NF-kappaB, TNF-alpha, IL-6, CRP, and PAI-1.
Conclusions:
- Subclinical inflammation is a critical factor in diabetic complications and arteriosclerosis.
- Targeting inflammation with agents like statins and ACE inhibitors is important for treatment.